Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Bonfrer

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 1, 1988
Why is breast cancer so frequent in The Netherlands?P F Bruning, J M Bonfrer, A Ansink, et al.
Cancer|July 1, 1996
CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?E M Davelaar, J M Bonfrer, R A Verstraeten, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1994
Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18J M Bonfrer, E M Groeneveld, C M Korse, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 1, 1993
Reliability of serum prolactin measurements in womenK L Koenig, P Toniolo, P F Bruning, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1997
Effect of paclitaxel (Taxol) on CA 125 expression and release by ovarian cancer cell linesJ M Bonfrer, T C Linders, P C Hageman, et al.
Clinical Chemistry|March 1, 1997
Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference valueJ M Bonfrer, C M Korse, R A Verstraeten, et al.
International Journal of Cancer|April 15, 1987
Comparison of circulating MAM-6 and CEA levels and correlation with the estrogen receptor in patients with breast cancerJ Hilkens, J M Bonfrer, V Kroezen, et al.
The British Journal of Ophthalmology|January 21, 2006
Immunophenotypic markers to differentiate between benign and malignant melanocytic lesionsS Keijser, G S Missotten, J M Bonfrer, et al.
International Journal of Cancer|November 10, 2000
Serum insulin-like growth factor-I and breast cancerP Toniolo, P F Bruning, A Akhmedkhanov, et al.
Anti-Cancer Drugs|July 11, 1998
Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group)P F Bruning, J M Bonfrer, R Paridaens, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 1, 1988
Why is breast cancer so frequent in The Netherlands?P F Bruning, J M Bonfrer, A Ansink, et al.
Cancer|July 1, 1996
CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?E M Davelaar, J M Bonfrer, R A Verstraeten, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1994
Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18J M Bonfrer, E M Groeneveld, C M Korse, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 1, 1993
Reliability of serum prolactin measurements in womenK L Koenig, P Toniolo, P F Bruning, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1997
Effect of paclitaxel (Taxol) on CA 125 expression and release by ovarian cancer cell linesJ M Bonfrer, T C Linders, P C Hageman, et al.
Clinical Chemistry|March 1, 1997
Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference valueJ M Bonfrer, C M Korse, R A Verstraeten, et al.
International Journal of Cancer|April 15, 1987
Comparison of circulating MAM-6 and CEA levels and correlation with the estrogen receptor in patients with breast cancerJ Hilkens, J M Bonfrer, V Kroezen, et al.
The British Journal of Ophthalmology|January 21, 2006
Immunophenotypic markers to differentiate between benign and malignant melanocytic lesionsS Keijser, G S Missotten, J M Bonfrer, et al.
International Journal of Cancer|November 10, 2000
Serum insulin-like growth factor-I and breast cancerP Toniolo, P F Bruning, A Akhmedkhanov, et al.
Anti-Cancer Drugs|July 11, 1998
Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group)P F Bruning, J M Bonfrer, R Paridaens, et al.
Pageof 5